A KAIST research team developed a microfluidic-based drug screening chip that identifies 

synergistic interactions between two antibiotics in eight hours. This chip can be a cell-based

 drug screening platform for exploring critical pharmacological patterns of antibiotic interactio

ns, along with potential applications in screening other cell-type agents and guidance for clini

cal therapies.

Antibiotic  susceptibility  testing,  which  determines  types  and  doses  of antibiotics that can 

effectively inhibit bacterial growth, has become more critical in recent years with the emergence 

of antibiotic-resistant pathogenic bacteria strains.